Growth Metrics

Aligos Therapeutics (ALGS) Change in Cash (2021 - 2025)

Aligos Therapeutics filings provide 5 years of Change in Cash readings, the most recent being -$23.6 million for Q4 2025.

  • On a quarterly basis, Change in Cash fell 1519.15% to -$23.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$18.7 million, a 81.05% increase, with the full-year FY2025 number at -$18.7 million, up 81.05% from a year prior.
  • Change in Cash hit -$23.6 million in Q4 2025 for Aligos Therapeutics, down from $23.3 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $65.3 million in Q4 2023 to a low of -$111.4 million in Q1 2024.
  • Median Change in Cash over the past 5 years was -$7.4 million (2022), compared with a mean of -$10.1 million.
  • Biggest five-year swings in Change in Cash: soared 1390.45% in 2023 and later plummeted 4551.65% in 2024.
  • Aligos Therapeutics' Change in Cash stood at -$53.4 million in 2021, then soared by 90.53% to -$5.1 million in 2022, then soared by 1390.45% to $65.3 million in 2023, then tumbled by 97.45% to $1.7 million in 2024, then tumbled by 1519.15% to -$23.6 million in 2025.
  • The last three reported values for Change in Cash were -$23.6 million (Q4 2025), $23.3 million (Q3 2025), and -$55.1 million (Q2 2025) per Business Quant data.